Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5397188 | 0.88 | PGR (0.43) | CA1CA2CA7CA9PGR | |
| SCHEMBL14428501 | 0.88 | TNFSF11 (0.55) | CA1CA2CA7CA9PGR | |
| SCHEMBL5400962 | 0.86 | ACHE (0.45) | CA1CA2CA7CA9PGR | |
| SCHEMBL8595488 | 0.86 | PGR (0.50) | CA1CA2CA7CA9PGR | |
| SCHEMBL4233485 | 0.86 | ACHE (0.45) | CA1CA2CA7CA9PGR | |
| SCHEMBL6554850 | 0.84 | PDE4B (0.37) | CA1CA2CA7CA9PGR | |
| SCHEMBL6553226 | 0.84 | PDE4B (0.37) | CA1CA2CA7CA9PGR | |
| SCHEMBL14428500 | 0.83 | PDE4A (0.41) | CA1CA2CA7CA9PGR | |
| SCHEMBL21344820 | 0.83 | CA1 (0.46) | CA1CA2CA7CA9KDM4E | |
| Indene SCHEMBL28198638 | 0.80 | TUBB4A (0.37) | PGRKDM4EALDH1A1HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109475490-A | Hair care composition containing wheat bran extract | 西姆莱斯股份公司 | 2019-03-15 | — | — | CN | disclosed |
| CN-109310620-A | A kind of Haircare composition | 西姆莱斯股份公司 | 2019-02-05 | — | — | CN | disclosed |
| US-9676691-B2 | Method for producing indanone derivatives | SYMRISE AG (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9676691-B2 | Method for producing indanone derivatives | SYMRISE AG (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9676691-B2 | Method for producing indanone derivatives | SYMRISE AG (DE) | 2017-06-13 | — | — | US | disclosed |
| EP-2404595-B1 | Method for manufacturing indanone derivatives | SYMRISE AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| EP-2404595-B1 | Method for manufacturing indanone derivatives | SYMRISE AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-20150071866-A1 | METHOD FOR PRODUCING INDANONE DERIVATIVES | SYMRISE AG (DE) | 2015-03-12 | — | — | US | disclosed |
| US-20150071866-A1 | METHOD FOR PRODUCING INDANONE DERIVATIVES | SYMRISE AG (DE) | 2015-03-12 | — | — | US | disclosed |
| US-20150071866-A1 | METHOD FOR PRODUCING INDANONE DERIVATIVES | SYMRISE AG (DE) | 2015-03-12 | — | — | US | disclosed |
| WO-2002086878-A2 | OPTICAL DATA CARRIER WHOSE INFORMATION LAYER CONTAINS A LIGHT-ABSORBING COMPOUND HAVING A NUMBER OF CHROMOPHORIC CENTERS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-10-31 | — | — | WO | disclosed |
| US-20020155381-A1 | Optical data carrier comprising a light-absorbent compound having a plurality of chromophoric centres in the information layer | LANXESS DEUTSCHLAND GMBH (DE) | 2002-10-24 | — | — | US | disclosed |
| US-20020143203-A1 | Novel indanylidene compounds | SYMRISE GMBH & CO. KG (DE) | 2002-10-03 | — | — | US | disclosed |
| US-6416746-B1 | ULTRAVIOLET RAY AND LIGHT SCREENING MATERIAL GRAFTED TO SILANE, OLIGOSILOXANE, OR POLYSILOXANE WITH IMPROVED SOLUBILITY AND LITTLE PENETRATION; FOR USE IN COSMETICS | ROCHE VITAMINS INC. | 2002-07-09 | — | — | US | disclosed |
| WO-2002038537-A1 | NOVEL INDANYLIDENE COMPOUNDS | HAARMANN & REIMER GMBH (DE) | 2002-05-16 | — | — | WO | disclosed |
| US-20020042414-A1 | Diamide compound and medicine containing the same | KOWA CO., LTD. (JP) | 2002-04-11 | — | — | US | disclosed |
| US-6340682-B1 | FOR THERAPY OF ALLERGIC IMMUNOLOGICAL DISEASE IS SELECTED FROM ASTHMA, ALLERGIC RHINITIS, INFLAMMATORY LARGE BOWEL DISEASE OR CONTACT DERMATITIS | KOWA CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| CN-1253943-A | New 2,3-dihydroindene compound | HOFFMANN LA ROCHE (CH) | 2000-05-24 | — | — | CN | disclosed |
| EP-1000950-A2 | Novel indanylidene compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2000-05-17 | — | — | EP | disclosed |
| EP-0926138-A1 | DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO. LTD. (JP) | 1999-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143203-A1 | Novel indanylidene compounds | CUTA, NISCH, ERCC4 | CA1 4843/4885CA2 4645/4885CA7 4120/4885 |
| US-20020042414-A1 | Diamide compound and medicine containing the same | HRH4, HRH2, HRH1 | CA1 639/4885CA2 40/4885CA7 210/4885 |
| US-20150071866-A1 | METHOD FOR PRODUCING INDANONE DERIVATIVES | CYP1B1, IDH3B, CYP11B1 | CA1 3835/4885CA2 3261/4885CA7 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.